Company ProfilePremium

Katz Biotech AG

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Katz Biotech AG - Company showcase

Year Founded & Workforce

1992

Katz Biotech AG logo

Katz Biotech AG Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Katz Biotech AG Overview

Note on headcount. A Patsnap estimate of "<10" employees is implausible against observable operations. Those operations include greenhouse rearing of 15 beneficial species at Baruth, a separate Berlin research centre with seven named research staff, a B2B and B2C e-commerce operation, and dedicated field advisers. In addition, North Data indicates the company has filed a profit and loss statement since FY2019, having previously filed a balance sheet only. Under German disclosure rules (§§ 267, 325–327 HGB), this pattern is consistent with the company moving out of the "small company" size class. That class is defined by thresholds on employees, revenue and balance-sheet total. This is an analytical inference, not a disclosed figure, and actual headcount remains not publicly disclosed.

Katz Biotech AG is an owner-managed German specialist in biological crop protection. Its core business is the mass rearing, sale and agronomic support of "Nützlinge", the beneficial insects, mites and nematodes used to control plant pests in greenhouses, horticulture, interior landscaping, private gardens and, more recently, livestock barns. The company rears about 15 beneficial species in-house at Baruth/Mark south of Berlin and resells more than 40 further products to offer a full range. It sells to commercial growers across Germany and the rest of Europe and to hobby gardeners through its own web shop. It is differentiated from far larger Benelux peers such as Koppert and Biobest by an unusually research-intensive model for its size. That model includes a Berlin insect-technology centre, a continuous stream of publicly funded collaborative research projects, and proprietary micro-encapsulation IP that underpins products such as nemaplus® Depot. It is a niche, family-controlled player in a consolidating global biocontrol industry.


What the company does

Katz Biotech AG produces and distributes living biological control agents ("macrobials"): predatory mites, parasitoid wasps, predatory insects and entomopathogenic nematodes. Growers release these to suppress pest populations instead of, or alongside, chemical pesticides. The company states that it rears 15 different beneficial species itself and buys in more than 40 further beneficial products to cover the full current range, and that it continually works to add new species and new biological methods (Über uns, katzbiotech.de, accessed Oct 2026).

Around this core, the business has four adjacent activity streams:

  1. Advisory services. On-site and remote consulting to integrate beneficials into growers' pest-management programmes. The company explicitly positions tailored advice as part of the offer, and in livestock farming it advertises free, non-binding consulting (Über uns; Herdenschutz page).

  2. Contract research and entomology services. From the Berlin ITC: rearing-process optimisation, synthetic diet development, new rearing methods, strain selection and isolation, sustainable shipping packaging, and supply of pest and beneficial insects for ecotoxicology studies (F&E page).

  3. Encapsulation technology services. The company offers to convert customers' liquid or oily diets, active ingredients, bacteria or entomopathogenic nematodes (EPNs) into spreadable capsule formats. It specialises in liquid-core and matrix capsules (F&E page).

  4. Training and knowledge products. The recurring "Pflanzenschutzstunde" webinar series, a beneficials brochure, posters and a YouTube channel (Aktuelles page).

Business and revenue model

Revenue streamNatureDisclosure status
Sale of self-reared beneficials (approx. 15 species)Product, recurring and seasonal; living perishable goods shipped to orderRevenue n/d
Resale of bought-in beneficial products (40+)Product (distribution / trading margin)Revenue n/d
Proprietary formulated products (e.g. nemaplus® Depot capsules)Product, IP-protectedRevenue n/d
Livestock fly control (e.g. VENDEX)Product plus advisoryRevenue n/d
Contract research and entomology servicesServiceRevenue n/d
Encapsulation development servicesService / potential licensingRevenue n/d
Public research grantsGrant income (other operating income)Individual awards disclosed in federal funding catalogue (see Section 13)

The mix between product, service and licensing revenue is not publicly disclosed. Based on the company's description, the business is predominantly a product business: living organisms sold per unit or per pack, priced per release quantity. Services and grants are a secondary, R&D-funding stream.

Value chain position

Katz Biotech is vertically integrated across:

Upstream: proprietary rearing (in-house colonies, host and diet systems, strain selection);

Midstream: packaging and cold-chain logistics of perishable living organisms;

Downstream: direct sale and agronomic advice to end users.

It also acts as a distributor for third-party beneficials to complete its range. This combination of producer, distributor and advisor is typical of mid-sized European insectaries.

Customer types and end-markets

Customer typeChannelEvidence
Commercial horticulture (greenhouse vegetables, ornamentals, nurseries)B2B shop (b2b.katzbiotech.de), advisers, annual commercial assortment listHome page; "Sortimentsliste 2026 für Gewerbekunden"
Retail garden centres / end-sale nurseriesB2B, advisory webinars on beneficial use in retailWebinar "Nützlingseinsatz im Endverkauf" (Aktuelles)
Private gardeners / households ("Haus und Garten")B2C web shopHome page
Organic and conventional fruit and vegetable growers (open field)Advisory and research projectsKOBE, BiWaReg, ParaDrosu projects (F&E)
Livestock farms (dairy, cattle barns)Dedicated Herdenschutz advisoryHerdenschutz page
Building-greening / interior landscapingKnowledge partner (HU Berlin webinar)Aktuelles page
Agrochemical / biologicals companies, research institutesEcotox insects, encapsulation, contract R&DF&E page

Geographically, the company states that its advice and deliveries cover Germany and the rest of Europe (Home page).

Company's own description vs independent characterisation

Company description (paraphrased). Since 1992 the company has specialised in producing and applying beneficial organisms for biological plant protection, serving horticultural businesses and private gardeners in Germany and across Europe. Its stated mission is to advance the role of beneficial insects in agriculture as an alternative to chemical pesticides (Home and Über uns pages). No annual report narrative is publicly accessible.

Independent characterisation. Katz Biotech is best characterised as a research-led German regional insectary with a disproportionately strong grant-funded innovation engine relative to its commercial scale. Its commercial core is a seasonal, logistics-intensive macrobial business exposed to greenhouse horticulture cycles. Its strategic optionality lies in:

  • encapsulation IP (liquid-core capsules for nematodes and attract-and-kill);

  • novel parasitoids for invasive pests (spotted-wing drosophila, invasive stink bugs);

  • insect-biomass and feed patents linked to a Hermetia (black soldier fly) holding;

  • automation of predatory-mite rearing.

It is a price-taker relative to the global leaders and relies on niche specialisation, proximity to German growers and advisory intimacy.

Strategy

Stated strategy (themes paraphrased from company communications)

No annual report narrative or investor-day material is publicly available. The website sets out the following strategic themes (paraphrased):

  1. Advance beneficial insects as the alternative to chemical pesticides. Clean food production, biodiversity protection, and the view that biological pest control is the future of agriculture (Home; Über uns).

  2. Customer intimacy through close cooperation with farmers, delivering tailored solutions (Über uns).

  3. Continuous expansion of the self-reared species range and development of new biological methods (Über uns).

  4. Innovation in rearing efficiency and application technology: automation, diets, lighting, encapsulation and drones (F&E).

  5. Sustainability in operations: packaging from renewable raw materials (F&E).

Strategic initiatives (last 24 months, Oct 2024 to Oct 2026)

InitiativeTypeStartTarget / goalStatusSource
Livestock fly control ("Herdenschutz") incl. VENDEXNew business linec. 2025–2026Enter biological fly control in animal husbandryLaunched; advisory activeHerdenschutz page
NemaKapsProduct development (encapsulated EPNs vs vegetable flies)Oct 2024Field-ready capsule applicationProject end Mar 2026; interim results presented 2026F&E; North Data
DHYNAMitePrecision biocontrol (drones plus hyperspectral detection)Aug 2025Detect spider-mite hotspots; targeted predator releaseOngoingNorth Data
AutoMiTecProduction automationJan 2026Solid-state bioreactor for automated predatory-mite propagationOngoingNorth Data
Resilience in organic vegetable growingPractice researchDec 2025Strategies and innovations for organic vegetablesOngoingNorth Data
BiWaRegNovel biocontrol agentApr 2022Trissolcus cultratus vs red-legged shield bugOngoing to Sep 2027F&E
Digital channel relaunch (B2C/B2B shops)Commercial infrastructurec. Sep 2024Separate commercial and consumer e-commerceLiveWebsite
Webinar programme ("Pflanzenschutzstunde")Customer education / marketingOngoingCustomer engagement, thought leadershipNext session 23 Nov 2026Aktuelles
Encapsulation-as-a-serviceTechnology commercialisationOngoingThird-party capsule developmentOfferedF&E

ESG commitments and cost programmes

ESG: no formal targets disclosed. The business model is inherently aligned with pesticide reduction.

Cost programmes: none disclosed. The AutoMiTec automation project implicitly targets lower rearing labour cost.

Medium-term financial targets and guidance

None published. The company does not issue guidance.

Products & Services

Important limitation. The company publishes a full commercial assortment list ("Sortimentsliste 2026 für Gewerbekunden") and a 2025 beneficials brochure as PDF downloads. The entries below are restricted to products and organisms verifiably named in public company or third-party material. Species not confirmed in company material are deliberately excluded rather than inferred from industry norms.

Crop protection – Commercial and Home & Garden

Product / offeringDescription and capabilityTarget customerLaunch / versionPricingSource
Self-reared beneficials range (about 15 species)Insects and mites reared at Baruth for release against greenhouse and garden pestsGrowers, gardenersOngoing since 1992Per pack or release unit; prices in web shop (n/d in summary)Über uns
Bought-in beneficial products (40+)Third-party beneficials to complete the rangeGrowers, gardenersOngoing—Über uns
Phytoseiulus persimilis (predatory mite)Specialist predator of spider mites; presented by Dr. Katz as part of the range in 2007Greenhouse vegetables, ornamentalsLong-standing—DPG protocol 2007
nemaplus® DepotSteinernema feltiae nematodes embedded in liquid-core capsules. Capsules are worked into potting soil and release nematodes as they dissolve or are chewed by larvae. The nematodes then infect fungus-gnat larvae via a symbiotic bacterium. Described as preventive and safe for people and pets.Houseplant owners, growers, retailCo-developed with e-nema GmbH; company describes it as worldwide unique—F&E page; nemaplusdepot.com; BioProtection Portal
Encapsulated EPNs against vegetable flies (NemaKaps)Capsule-based nematode delivery against vegetable flies (e.g. cabbage and onion fly types); interim results presented in 2026 webinarField vegetable growersDevelopment (project to Mar 2026)Not commercial yetF&E; Aktuelles
Pupal parasitoids vs. Drosophila suzukii (e.g. Trichopria drosophilae)Practical release of pupal parasitoids against spotted-wing drosophila (ParaDrosu)Berry, cherry and fruit growersResearch 2021–2025; commercial status n/d—F&E
Trissolcus cultratus (egg parasitoid)Biological control of red-legged shield bug in organic orchards (BiWaReg)Organic fruit growersResearch to 2027Not commercial yetF&E
Attract-and-kill capsule system ("A&K principle")Capsules with an attractant in the outer shell. Bugs pierce the capsule and ingest the control agent from the aqueous core. Claimed benefits: no crop contact with the plant-protection product, no pre-harvest interval, lower active-ingredient use, high selectivity, suitability for UV-unstable biologicals, machine application.Fruit and vegetable growers; agrochemical partnersDevelopment / technology platform—F&E page

Livestock / Herd protection

Product / offeringDescriptionTarget customerLaunchPricingSource
VENDEXNew product against stable flies, specifically house fly (Musca domestica) and stable fly (Stomoxys calcitrans). Positioned to lower disease-transmission risk, reduce chemical reliance and be safe for humans and animals. The organism or mode of action is not specified on the public page.Dairy and livestock farmsc. 2026 ("Neu in unserem Sortiment")—Herdenschutz page
Beneficials concepts for animal housingFarm-specific biological pest-control strategies with free advisory, led by an agricultural engineer with 25+ years of dairy experienceFarms, agricultural cooperativesc. 2025Advisory free of chargeHerdenschutz page

R&D, Technology & Services (ITC Berlin)

OfferingDescriptionTarget customerSource
Rearing process optimisationEfficiency improvement in mass rearing of beneficialsInsectaries, partnersF&E
Synthetic diets for beneficialsDevelopment of new artificial feeding dietsInsectariesF&E
Novel rearing methodsNew insect rearing procedures; species-specific lighting (InLight); solid-state bioreactor for predatory mites (AutoMiTec)Internal; partnersF&E; North Data
Strain selection and isolationClassical breeding for high-quality beneficial strainsInternal QAF&E
Sustainable shipping packagingPackaging from renewable raw materials for living organismsInternal; customersF&E
Screening of new beneficial speciesEvaluation of little-studied natural enemiesInternal; researchF&E
Ecotox test organismsSupply of pest and beneficial insects for ecotoxicological studiesAgrochemical companies, CROs, regulatorsF&E; statutory object
Micro-encapsulation servicesLiquid-core and matrix capsules; aqueous or oily cores, emulsions and suspensions; optimisation of additives and process parametersBiologicals companies, diet developersF&E
Chemical entomologyDedicated service area (details on sub-page)Research partnersF&E (C-E link)

Knowledge products (non-revenue / marketing)

ItemDescriptionSource
"Pflanzenschutzstunde" webinar seriesWebinars with in-house and external experts (e.g. HU Berlin); next session 23 Nov 2026Aktuelles
Beneficials brochure (2025 edition)Guide to common pests and their natural enemies with application tipsAktuelles
Commercial assortment list 2026Full B2B price and product list (PDF)Aktuelles
Posters and YouTube channelEducational contentAktuelles

Financial Narrative

Disclosure context

Katz Biotech AG files HGB single-entity annual accounts with the German company register. North Data indexes balance sheets for FY2005–FY2024 and profit and loss statements for FY2019–FY2024. As a result, every financial line item below is not publicly disclosed in the accessible sources. No estimates are provided.

Primary-source route for users: the FY2020–FY2024 accounts can be retrieved from the German Unternehmensregister (unternehmensregister.de) under Katz Biotech AG, Amtsgericht Potsdam HRB 16819 P. The accessible publication dates are listed in 6.6.

Blank cells below mean not publicly disclosed.

Income statement

Revenue CAGR FY2020–FY2024: not calculable (n/d).

EPS is not a meaningful metric for an unlisted AG with a closely held share register. The share count is not publicly disclosed; share capital was EUR 100,000 as of the 2007 publication.

Balance sheet

The subscribed capital row assumes no change since the EUR 100,000 capital publication of 20 March 2007. No later capital-change publication appears in the accessible register index.

Cash flow

Cash flow statements are not required for non-capital-market HGB single-entity accounts. They are therefore likely not prepared for publication at all, not merely inaccessible.

Commentary on trends, inflections and drivers

In the absence of numbers, the analysis relies on qualitative evidence.

(i) Size inflection around FY2019. The switch from balance-sheet-only to balance sheet plus P&L publication from FY2019 is the single most informative public signal about scale. Under German law, this disclosure change typically follows a company exceeding two of the three small-company thresholds for two consecutive years. It points to growth through the late 2010s in headcount, revenue or balance-sheet total.

(ii) Filing cadence. The FY2024 accounts were published about 13 months after year end (February 2026). Earlier years were also published about 12 months after year end. This is consistent with statutory deadlines and does not signal distress, but the cadence has drifted later.

(iii) Revenue drivers. Revenue drivers are likely to include:

  • German greenhouse vegetable and ornamental acreage and their adoption of integrated pest management (IPM);

  • the spread of invasive pests creating new demand, for example Drosophila suzukii, Halyomorpha halys and Nezara viridula;

  • the regulatory withdrawal of chemical actives in the EU;

  • weather-driven seasonal pest pressure.

(iv) Grant income as a stabiliser. Federal grants of EUR 0.18–0.40 million per year in award terms are material relative to a company of this type. They likely represent a meaningful share of R&D funding.

(v) Cost pressures. Energy costs for heated greenhouse rearing, labour costs and logistics for living goods were material headwinds for European insectaries in 2022–2023. The company's specific exposure is not publicly disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (analytical)ContentsProducts / services

A. Crop protection – Commercial (B2B)

Beneficials for greenhouse and field horticulture, nurseries, retail growers

15 self-reared species, 40+ bought-in products, advisory

B. Home & Garden (B2C)

Beneficials for private gardens, houseplants and interiors

Web shop, nemaplus® Depot (fungus gnats)

C. Livestock / Herd protection

Biological fly control in animal housing

VENDEX, advisory concepts

D. R&D, Contract research & Technology services

ITC Berlin: entomology services, ecotox organisms, encapsulation, publicly funded projects

Contract R&D, capsule development, grants

Group Entities

EntityRelationshipEvidenceStatus

Katz Biotech AG

Operating parent

Register HRB 16819 P

Active

Hermetia GbR

Holding disclosed in FY2009 accounts

North Data

Current status n/d

PK Nützlingszuchten und Hermetia GbR

Holding disclosed in FY2012 and FY2013 accounts

North Data

Current status n/d

Further holdings

4 holdings (FY2014), 5 holdings (FY2015) per accounts

North Data

Names and stakes n/d

Key Financials

MetricFY2020FY2021FY2022FY2023FY2024

Subscribed capital (EUR Mn)

0.10.10.10.10.1

Contents Published by Fiscal Year

Fiscal yearContents publishedPublication dateSource

FY2024

Balance sheet, P&L, persons

9 Feb 2026

North Data

FY2023

Balance sheet, P&L, persons

3 Jan 2025

North Data

FY2022

Balance sheet, P&L, persons

1 Mar 2024

North Data

FY2021

Balance sheet, P&L

10 Jan 2023

North Data

FY2020

Balance sheet, P&L

14 Dec 2021

North Data

FY2019

Balance sheet, P&L

16 Dec 2020

North Data

FY2018

Balance sheet only

9 Dec 2019

North Data

FY2017

Balance sheet only

12 Dec 2018

North Data

FY2016

Balance sheet only

24 Nov 2017

North Data

FY2015

Balance sheet; 5 holdings

2 Dec 2016

North Data

FY2014

Balance sheet; persons; 4 holdings

7 Dec 2015

North Data

Capital Markets

ItemStatus

Share price performance (1 / 3 / 5 years)

Not applicable; unlisted

Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B)

Not applicable; unlisted

Analyst consensus

None; no coverage

Buyback authorisations

None disclosed

Credit ratings (Moody's / S&P / Fitch)

Not rated

Share capital

EUR 100,000 (publication 20 Mar 2007)

Capital Markets Data

MetricFY2021FY2022FY2023FY2024FY2025

Share capital (EUR Mn)

0.10.10.10.10.1

Analyst Conclusions

Management guidance

None published.

Consensus expectations

None; no analyst coverage.

Bull case

  1. Capsule IP becomes a licensable platform. Liquid-core capsule patents (DE/EP/WO/US/CA) and the proven nemaplus® Depot product could be licensed to larger nematode or biologicals firms, decoupling revenue from rearing scale.

  2. New markets compound. Livestock fly control (VENDEX, 2026) and invasive-pest parasitoids (ParaDrosu, BiWaReg) open demand pools where Katz has first-mover know-how in Germany.

  3. Automation closes the cost gap. AutoMiTec (EUR 287k, 2026) and InLight-type process gains could structurally lower rearing cost in predatory mites, the highest-volume macrobial category.

Bear case

  1. Scale economics win. Koppert (EUR 435m revenue) and Biobest can underprice regional insectaries. Katz's reliance on 40+ bought-in products may mean partly reselling competitors' goods at thin margins.

  2. R&D does not convert. A long sequence of grant projects since 2017 has produced one clearly named commercial capsule product. Several projects remain pre-commercial (BiWaReg to 2027).

  3. Governance and succession. A founder-led, single-Vorstand, family-chaired structure, together with opaque financials and a EUR 0.1m capital base, limits growth capital and raises continuity risk.

Key catalysts and monitorables (next 12 months)

  1. Publication of the FY2025 accounts (expected around Q1 2027, based on historical cadence). Key items: revenue (P&L disclosed), equity ratio and indebtedness.

  2. Commercial follow-through from NemaKaps (completed March 2026), for example a field-vegetable capsule product.

  3. Market traction and any extension of VENDEX and the Herdenschutz range.

  4. AutoMiTec and DHYNAMite milestones.

  5. Any change in Vorstand or Aufsichtsrat composition, or § 20 AktG shareholding notices signalling ownership change or a sale.

  6. Status of the US liquid-core capsule application (17/789,913).

  7. Sector M&A involving German insectaries.

Analyst verdict

Katz Biotech AG is not the "public company" the input list assumed. It is a family-controlled, unlisted German Aktiengesellschaft that has quietly assembled one of the more research-intensive profiles among Europe's second-tier beneficial-insect producers. Its corporate DNA combines an East German production lineage dating to 1980 with a West German founder-entrepreneur who started rearing beneficials in a basement in 1992. That heritage has produced a company with credible biological craft (about 15 species reared in-house), a full-range commercial offer and a durable relationship with Germany's public research system.

The investment-relevant question is whether that research engine can be monetised fast enough to offset structural scale disadvantages. Public evidence is mixed:

On the positive side: the encapsulation platform is real, patented across several jurisdictions and commercialised with e-nema. The company is also extending into livestock fly control and precision application, where incumbency is weak.

On the negative side: the global market is consolidating around players with hundreds of millions in revenue and private-equity backing. Katz still buys in most of its product range. Its R&D pipeline is long-dated and grant-dependent; there were no new federal awards in 2022–2023 before a rebound in 2024–2026.

Governance is the overriding uncertainty. A sole founder-Vorstand, a family supervisory-board chair, shareholder notifications in 2018 and a supervisory board change in 2025 all point to an ownership structure whose future intent is undisclosed.

Without access to the filed HGB financials, no view on valuation, profitability or leverage can responsibly be offered. Any counterparty, lender or acquirer should retrieve the FY2019–FY2024 accounts from the Unternehmensregister as a first step.

Overall assessment: a technically differentiated, strategically interesting niche asset, best viewed as a potential partnership, licensing or bolt-on acquisition target rather than a standalone scale player. Confidence in this view is low to moderate, constrained by the absence of verifiable financial data.


APPENDIX — SOURCE LIST

1: Katz Biotech AG – Home — https://katzbiotech.de

2: Katz Biotech AG – Impressum — https://katzbiotech.de/Menue/Impressum/

3: Katz Biotech AG – Über uns — https://katzbiotech.de/Ueber-Uns

4: Katz Biotech AG – Aktuelles — https://katzbiotech.de/Aktuelles

5: Katz Biotech AG – F&E — https://katzbiotech.de/F-E

6: Katz Biotech AG – Herdenschutz (B2B) — https://b2b.katzbiotech.de/Herdenschutz/

7: North Data – Katz Biotech AG, HRB 16819 P — https://www.northdata.de/Katz+Biotech+AG,+Baruth/Amtsgericht+Potsdam+HRB+16819+P

8: Patsnap Discovery – Katz Biotech — https://discovery.patsnap.com/company/katz-biotech

9: IPQwery – Katz Biotech AG patents — https://ipqwery.com/ipowner/en/owner/ip/5535736-katz-biotech-ag.html

10: Craft.co – Katz Biotech — https://craft.co/katz-biotech

11: 11880.com – Katz Biotech AG directory — https://www.11880.com/branchenbuch/baruth-mark/250321015B28945384/katz-biotech-ag.html

12: BioProtection Portal – e-nema / Katz Biotech capsules — https://bioprotectionportal.com/news/page/68

13: DPG Phytomedizin – Protocol PG 2007 — https://phytomedizin.org/fileadmin/documents/Ak/21_Kraueter/Doku/PROTOKOLL_PG2007.pdf

14: Orgprints – Peters, Katz, Elias (2008) — https://orgprints.org/view/creators/Katz=3AP=2E=3A=3A.html

15: Sächsische Gartenakademie – Suppliers of beneficials — https://www.gartenakademie.sachsen.de/download/Bezugsquellen_fuer_Nuetzlinge_Kleingarten.pdf

16: HAL Investments – Koppert — https://www.halinvestments.nl/koppert/

17: Doriane – Top 10 biologicals companies 2025 — https://www.doriane.com/blog/the-top-10-biologicals-companies-in-2025

18: AgFeed – Koppert in Brazil — https://agfeed.com.br/negocios/donos-da-koppert-lider-global-em-biologicos-invadem-a-america-a-partir-do-brasil

19: The AgriBiz – Koppert Brazil financials — https://www.theagribiz.com/?p=315458

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundEducation

Dr. Peter Katz

Management Board (Vorstand), founder

Founder since 1992; Vorstand since at least the 2006 register entry

Founded PK-Nützlingszuchten (1992); presenter at DPG phytomedicine forums (2007); co-author on EPN research against codling moth (2008); named inventor on company patents

Doctorate (subject n/d)

Jörg Rademacher

Head of R&D (Leiter F&E), ITC Berlin

—

Named co-inventor on liquid-core capsule patent

Diplom-Biologe

Dr. Markus Hellmund

Research scientist (encapsulation / NemaKaps)

—

Co-inventor on liquid-core capsule patent; NemaKaps presenter (2026)

Diplom-Chemiker, Dr. rer. nat.

Dr. Benjamin Walliser

Research scientist

——

M.Sc. Agrobiotechnology, Dr. rer. nat.

Ghita Della Pasqua

Research scientist

——

M.Sc. Crop Sciences

Sanjana Palika

Research scientist

——

M.Sc. Agricultural Entomology

Christoph Hoff

Biological-technical assistant

——

BTA

Vivien Hördel

Biological-technical assistant

——

BTA

Martin Kamphusmann

Adviser (retail / end-sale beneficial use)

—

Webinar presenter 2026

—

Ralf Weber

Livestock (Herdenschutz) adviser

c. 2025–

25+ years in dairy production; member of an examination board for agricultural trainees

Agricultural engineer (Agraringenieur)

Andrea Häussler

Named co-inventor (liquid-core capsules)

———

Board of Directors

NameRoleIndependenceSource

Kirsten Katz

Chair

Not independent in the conventional sense; family name indicates a family relationship with the CEO, but the precise relationship is not disclosed

Impressum

Other members

Members (German AG law requires a minimum of three)

—

Lists filed 2016 and May/June 2025 (contents not accessible)

Board & Management Changes

DateChangeContextSource

30 May / 13 Jun 2025

Updated list of supervisory board members filed

Indicates change in Aufsichtsrat composition; names n/d

North Data

c. 2025

Appointment of dedicated livestock adviser (Ralf Weber)

Supports the new Herdenschutz line

Herdenschutz page

Major Shareholders

HolderStakeSource

Holders notified under § 20 AktG (2018)

Holdings above statutory thresholds (25% / majority) notified; names and stakes n/d

North Data (three announcements Nov–Dec 2018)

Institutional ownership (top 10)

Not applicable / not publicly disclosed

—

Competitive Landscape

Key Competitors

CompetitorHQTypeOverlap with Katz BiotechScale indicatorSource

Koppert

Berkel en Rodenrijs, NL

Family-owned; HAL Investments 27.3%

Full macrobial range, greenhouse IPM, Germany and Europe

Revenue EUR 435m; EBITDA EUR 34m; 2,683 employees (HAL)

HAL Investments

Biobest (BioFirst Group)

Westerlo, BE

Private

Macrobials, pollination, biologicals

Targets USD 2bn biologicals revenue by 2035; acquired Biotrop 2023

Doriane; AgFeed

Syngenta Biologicals

Basel, CH

Corporate division

Biologicals (mainly microbials and biostimulants)

Biologicals revenue about USD 400m (as of Mar 2024)

Doriane

UPL (NPP)

IN / global

Corporate division

Natural plant protection

NPP revenue USD 365m (2024)

Doriane

FMC Biologicals

US

Corporate division

Biologicals

USD 240m (2024), +33%

Doriane

e-nema GmbH

Schwentinental, DE

Private

Entomopathogenic nematodes (also a partner)

—

Sachsen Gartenakademie list

Sautter & Stepper GmbH

Ammerbuch, DE

Private

Beneficials for gardens and professionals

—

Sachsen Gartenakademie list

Re-natur GmbH

Stolpe, DE

Private

Beneficials and biological plant protection

—

Sachsen Gartenakademie list

W. Neudorff GmbH KG

Emmerthal, DE

Private

Home and garden biologicals including beneficials

—

Sachsen Gartenakademie list

Andermatt Group / Bioline AgroSciences

CH / UK

Private

Macrobials and biologicals

—

Industry knowledge; figures n/d

Peer Comparison FY2025

MetricKoppertSyngenta Biologicals

Revenue

EUR 435m

about USD 400m

EBITDA margin

about 7.8% (EUR 34m / EUR 435m)

—

Employees

2,683

n/a (division)

Recent Developments

Not identified in the period: * guidance revisions, litigation, regulatory actions, restructurings, layoffs, or major contract wins.

Company Snapshot

1992

Founded

Brandenburg, Germany

Headquarters

SWOT Analysis

Strengths

  • Proprietary capsule IP: 17 patent documents (Patsnap), including the US application for liquid-core EPN capsules filed 5 Mar 2021.
  • Commercialised innovation: nemaplus® Depot, co-developed with e-nema, which the company describes as globally unique.
  • Grant-funding capability: federal grant awards of EUR 395k (2021), EUR 185k (2024), EUR 323k (2025) and EUR 287k (2026 YTD).
  • In-house rearing of 15 species plus 40+ bought-in products, giving a complete range offer.
  • Dedicated R&D centre (ITC Berlin) with a 7-person named scientific team.
  • Long heritage: origins in 1980 (Flora Nützlinge) and 1992 (PK-Nützlingszuchten), with continuous operation since.

Weaknesses

  • Scale disadvantage: Koppert alone reports EUR 435m revenue and 2,683 employees.
  • Range dependence: 40+ bought-in products are likely sourced partly from competitors.
  • Governance concentration: sole Vorstand (Dr. Peter Katz) and family chair (Kirsten Katz).
  • Low transparency: no publicly accessible revenue or earnings; accounts published about 12–13 months after year end.
  • Geographic concentration: a single production country (Germany).
  • Research projects are pre-commercial (BiWaReg runs to 2027), so they deliver delayed revenue.

Opportunities

  • Livestock biocontrol (VENDEX) opens a new, largely chemical-dominated market.
  • Invasive pests (D. suzukii, H. halys) create new demand, supported by ParaDrosu and BC-InStink results.
  • Encapsulation-as-a-service and licensing to larger biologicals players (US/CA patent filings).
  • Automation (AutoMiTec) could cut rearing cost and close the scale gap.
  • Precision biocontrol (DHYNAMite) aligns with digital agriculture.
  • Sector consolidation could yield a strategic partner or exit at an attractive valuation.

Threats

  • Consolidation of competitors: Biobest–Biotrop (2023), HAL investment in Koppert (2024).
  • Price pressure and destocking seen across the sector (Koppert Brazil revenue decline in 2024).
  • Energy cost volatility for heated greenhouse rearing.
  • Public funding dependence: changes to BMLE, BMBF or DBU programmes would hit R&D.
  • Regulatory risk for non-native beneficials and new active ingredients (attract-and-kill, RNAi).
  • Key-person risk for a founder-led company more than 30 years after founding (succession not disclosed).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 May 2025Supervisory board member list filed (original document) North DataGovernance change
13 Jun 2025Supervisory board list published North DataConfirms Aufsichtsrat change
25 Jun 2025Patent publication: carotenoid-enriched feed North DataExtends feed / insect-biomass IP
1 Aug 2025DHYNAMite grant awarded (EUR 209,276) North DataEntry into precision, drone-based biocontrol
c. Sep 2025Livestock beneficials range ("Herdenschutz") promoted on homepage WebsiteNew end-market
1 Dec 2025Organic-vegetable resilience grant (EUR 113,855) North DataOrganic sector positioning
31 Dec 2025KOBE project (DBU / Leibniz Universität Hannover) scheduled completion F&EOpen-field biocontrol know-how
1 Jan 2026AutoMiTec grant (EUR 287,412) North DataLargest new award since 2018; automation of predatory-mite production
Jan 2026Commercial assortment list 2026 published AktuellesAnnual range update
9 Feb 2026FY2024 annual accounts published North DataStatutory disclosure
c. Mar 2026VENDEX launched against stable flies Herdenschutz pageFirst named livestock product
31 Mar 2026NemaKaps project scheduled completion F&EPathway to field capsule product vs vegetable flies
2026Webinar: interim NemaKaps results (Dr. Markus Hellmund) AktuellesTechnology validation
2026Webinar: beneficial use in retail (Martin Kamphusmann) AktuellesRetail channel push
2026Webinar: plant health in building greening (HU Berlin) AktuellesNew niche exploration
1 Jul 2026Patent publication: value-enriched food or feed component North DataFeed IP continuation
22 Jul 2026Directory profile updated (Baruth, business hours) 11880.comOperational continuity
23 Nov 2026 (scheduled)Next "Pflanzenschutzstunde" webinar AktuellesCustomer engagement

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Income Statement

1 chart
Key Financials: Subscribed capital held from EUR 0.1 Mn in FY2020 to EUR 0.1 Mn in FY2024.
Katz Biotech AG — Key Financials
Series (EUR Mn)FY2020FY2021FY2022FY2023FY2024
Subscribed capital0.10.10.10.10.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.